Product logins

Find logins to all Clarivate products below.


The Company Franchise Analysis (CFA) provides a comprehensive evaluation of the franchise, including benchmarking, strategic insights, and an overview of marketed products. It highlights key market drivers and offers a detailed pipeline and sales analysis, along with information on deals and significant events. This profile aims to deliver a thorough understanding of the market dynamics and the strategic positioning of the franchise’s drugs.

Related Market Assessment Reports

Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…
Report
Thyroid Eye Disease – Executive Insights – Thyroid Eye Disease | Executive Insights (US)
Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula, leading to vision impairment and…
Report
Biosimilars – Forecast – Ophthalmology
In 2023, sales of branded biologics in ophthalmology exceeded $9.2 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period…
Report
Dry Eye – Landscape & Forecast – Disease Landscape & Forecast (G7)
Dry eye disease (DED) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. The DED market is evolving rapidly, driven by…